Inhibition of IDH1 mutant promoted cycling of LSCs.335 A genomic analysis was performed in R/R AML patients with IDH mutations who received ivosidenib (IDH1 inhibitor) treatment, and the results suggested that primary resistance to ivosidenib was correlated with RTK pathway mutations.336,337IDH2 mutation cooperated with a NUP98-HOXD13 fusion caused early immature thymocyte precursor ALL.338. This evidence concerns the gene IDH2 and acute myeloid leukemia.